AYN RANDiano2
Será en Octubre
- Desde
- 14 May 2010
- Mensajes
- 104.874
- Reputación
- 623.406
No se me ocurre una síntesis literaria que describa mejor de las "drojas anti-VIH salvadoras de vidas".
CAJÓN DE SASTRE DE MAGUFADAS:
Tengo delante mío una revista de divulgación científica "Algo" que compré personalmente en febrero de 1986.
Os transcribo lo que viene en esta revista:
PORTADA: Los laboratorios donde se está venciendo al cáncer.
PÁGINA 3: EL CANCER ESTÁ ACORRALADO
PÁGINA 29: Pero todo hace pensar que está próximo el día de la victoria final del hombre contra el cáncer
PÁGINA 3: EL CANCER ESTÁ ACORRALADO
PÁGINA 29: Pero todo hace pensar que está próximo el día de la victoria final del hombre contra el cáncer
Esta revista tiene ya UN CUARTO DE SIGLO de antiguedad.
Más magufadas:
1984. Anuncian "banderilla contra el SIDA" para 1986 (Gallo) o para 1989 (Montagnier):
'Sida, el enigma puede resolverse', Informe Semanal (1984), Informe Semanal - RTVE.es A la Carta
1986: Anuncian "banderilla contra el SIDA" para... el año 2000.
Erratum. [Science. 1986] - PubMed - NCBI
A ver si aprendéis de una vez que nos están tomando el pelo a todos con estos "avances inminentes".
The frequent isolation of HTLV-III from patients with AIDS and ARC, the detection of antibodies specific for HTLV-III in nearly all patients with these diseases and in a high proportion of individuals at risk, and finally its effect on cells in vitro, leaves little doubt that HTLV-III is causatively involved in the development of these diseases
Etiology of AIDS: biological and biochemica... [Adv Exp Med Biol. 1985] - PubMed - NCBI
Etiology of AIDS: biological and biochemica... [Adv Exp Med Biol. 1985] - PubMed - NCBI
The serologic testing provided clear evidence that tropical African Kaposi's sarcoma is not associated with HTLV-III infection; non of the 217 serum samples analyzed from the 3 study groups showed antibodies to this bichito
Kaposi's sarcoma and HTLV-III: a study in Nigeri... [J R Soc Med. 1986] - PubMed - NCBI
Kaposi's sarcoma and HTLV-III: a study in Nigeri... [J R Soc Med. 1986] - PubMed - NCBI
HTLV-III/LAV was isolated in peripheral blood samples from 8 of 12 men tested. Culture-positive and culture-negative men did not differ significantly in terms of age, presence of a palpable lymph node, T helper:T-suppressor cell ratio, or duration of seropositivity. These findings suggest that some seropositive men may remain asymptomatic for at least 5 years. However, the isolation of HTLV-III/LAV from the peripheral blood of most of these men indicates persistent infection may be common among asymptomatic seropositive men at risk for AIDS. It should be assumed that these men have the potential to transmit HTLV-III/LAV infection
Persistent infection with human T-lymphotropi... [Ann Intern Med. 1985] - PubMed - NCBI
Persistent infection with human T-lymphotropi... [Ann Intern Med. 1985] - PubMed - NCBI
These results show that Kaposi's sarcoma in Nigeria is not associated with infection with the AIDS bichito and that the bichito is not endemic in this region...The results of the study showed that none of the 40 patients with KS, the 30 patients with malignant melanoma or the 50 normal controls had antibody against AIDS.
Antibody to the AIDS bichito in Kaposi's sarcoma ... [J Surg Oncol. 1988] - PubMed - NCBI
Antibody to the AIDS bichito in Kaposi's sarcoma ... [J Surg Oncol. 1988] - PubMed - NCBI
Abstract
Kaposi's sarcoma, first described in 1972, is a rare, chronic neoplasm that occurs most often in elderly men of Eastern European origin. In the mid-twentieth century, more aggressive forms of Kaposi's sarcoma were found to be an endemic disease especially common among young black men in central Africa. Kaposi's sarcoma also occurs in iatrogenically immunosuppressed patients, such as kidney transplant recipients. In 1981, the sudden occurrence of an unusual, disseminated form of Kaposi's sarcoma in gays men in New York and California heralded the epidemic now known as the acquired immunodeficiency syndrome (AIDS). Ninety-five percent of all AIDS-associated Kaposi's sarcoma (AIDS-KS) has been in gays men; however, the incidence of AIDS-KS has diminished from greater than 40% of men with AIDS since 1981 to less than 20% in 1989. The remaining 5% of AIDS-KS has been seen in all other populations at risk for AIDS. The reasons for the remarkable persistent increased prevalence of AIDS-KS among gays men remains obscure. Clinically, AIDS-KS is a highly varied neoplastic disease characterized by multifocal mucocutaneous lesions often with lymphatic and visceral involvement. The etiology of Kaposi's sarcoma remains unknown although various hypotheses have been suggested, including endothelial-tumor growth factors, oncogenic expression, genetic predisposition, and environmental cofactors. An as-yet unidentified viruslike agent has been proposed as a possible direct cause of this neoplasm. Different treatment modalities for Kaposi's sarcoma have been employed with varying success, these include localized radiation therapy, cryotherapy, electrocauterization, surgical excision, and a variety of systemic chemotherapeutic regimens, as well as alpha-interferon. Although all available treatments help control the lesions, none lengthens survival.
Clinical manifestations of classical, end... [J Am Acad Dermatol. 1990] - PubMed - NCBI
Kaposi's sarcoma, first described in 1972, is a rare, chronic neoplasm that occurs most often in elderly men of Eastern European origin. In the mid-twentieth century, more aggressive forms of Kaposi's sarcoma were found to be an endemic disease especially common among young black men in central Africa. Kaposi's sarcoma also occurs in iatrogenically immunosuppressed patients, such as kidney transplant recipients. In 1981, the sudden occurrence of an unusual, disseminated form of Kaposi's sarcoma in gays men in New York and California heralded the epidemic now known as the acquired immunodeficiency syndrome (AIDS). Ninety-five percent of all AIDS-associated Kaposi's sarcoma (AIDS-KS) has been in gays men; however, the incidence of AIDS-KS has diminished from greater than 40% of men with AIDS since 1981 to less than 20% in 1989. The remaining 5% of AIDS-KS has been seen in all other populations at risk for AIDS. The reasons for the remarkable persistent increased prevalence of AIDS-KS among gays men remains obscure. Clinically, AIDS-KS is a highly varied neoplastic disease characterized by multifocal mucocutaneous lesions often with lymphatic and visceral involvement. The etiology of Kaposi's sarcoma remains unknown although various hypotheses have been suggested, including endothelial-tumor growth factors, oncogenic expression, genetic predisposition, and environmental cofactors. An as-yet unidentified viruslike agent has been proposed as a possible direct cause of this neoplasm. Different treatment modalities for Kaposi's sarcoma have been employed with varying success, these include localized radiation therapy, cryotherapy, electrocauterization, surgical excision, and a variety of systemic chemotherapeutic regimens, as well as alpha-interferon. Although all available treatments help control the lesions, none lengthens survival.
Clinical manifestations of classical, end... [J Am Acad Dermatol. 1990] - PubMed - NCBI
In the absence of a specific etiologic agent or diagnostic test, a case can only be recognized when complications of the immune deficiency such as infection or Kaposi's sarcoma occur
Infectious complications of the acquired im... [Ann N Y Acad Sci. 1984] - PubMed - NCBI
A. I. D. S. K. S K. S. + O. I.
[Problems raised by the treatm... [Bull Soc Pathol Exot Filiales. 1984] - PubMed - NCBI
[Treatment of Kaposi's sarcoma].
[Article in French]
Coulaud JP.
Abstract
To conclude, no completely satisfactory form of therapy is available at the moment. Combinations are always desirable: either radiotherapy and chemotherapy
[Treatment of Kaposi's sarcoma]. [Bull Soc Pathol Exot Filiales. 1984] - PubMed - NCBI
About 35% of all AIDS patients and 50% of gays or bisexual victims have developed Kaposi's sarcoma, and those with coincident opportunistic infection have 2.5 times the mortality of those without such infection. There are 2 essential antiestéticatures to the histopathology of Kaposi's sarcoma: 1) vascular proliferation and 2) spindle-shaped neoplastic cells in a network of reticulin fibers that appear to be of endothelial origin. The treatment of the epidemic form of Kaposi's sarcoma has not been successful, and the projected 2-year survival is only 30%. The causes of death in the majority of such patients are overwhelming opportunistic infections, especially cytomegalovirus and Pneumocystis carinii, and irreversible cachexia and wasting. Interferon therapy has had a beneficial effect in patients with disease limited to skin, with T4/T8 ratios over 0.5, and without a prior history of opportunistic infection; however, there is no evidence that interferon exerts any beneficial effects on the underlying immune defects. An aggressive 6-drug combination chemotherapy regimen has been tried on patients whose tumors appeared to be life-threatening and was effective in controlling the Kaposi's sarcoma, but again did not appreciably alter immune parameters. Several other approaches to the treatment of epidemic Kaposi's sarcoma are under evaluation, including gamma interferon, interleukin-2, and plasmapheresis. Patients who develop malignant lymphomas require combined treatment with central nervous system radiation and systemic combination chemotherapy. There is no evidence that the antitumor responses obtained in AIDS-related malignancies translate into survival advantages
Malignancies in the AIDS patient: natural h... [Ann N Y Acad Sci. 1984] - PubMed - NCBI
it has been found in body tissues and fluids including brain, leche, and saliva.
NIH conference. The acquired immunodeficiency... [Ann Intern Med. 1985] - PubMed - NCBI
the presence of specific antibody should be considered presumptive evidence of current infection
The epidemiology of AIDS: current status and future ... [Science. 1985] - PubMed - NCBI
A guide to the investigation and treatment of patients with AIDS and AIDS-related disorders. (exclusión de "VIH-" con síntomas)
By the 1930s, nitrites and nitrate esters were established treatments for angina and hypertension
Nitrates and Nitrites in the Treatment of Ischemic Cardiac Disease
Amyl nitrite as a sensual stimulant.
Irradiation can provide good to excellent palliation with only minimal side effects, and will produce a lesser impact on the hematological and immunological systems than chemotherapy. Therefore, we advocate the liberal employment of palliative radiation therapy in patients with AIDS.
PMID: 2433407 [PubMed - indexed for MEDLINE]
The impact of palliative irradiation on the man... [J Clin Oncol. 1987] - PubMed - NCBI
The Acquired Immunodeficiency Syndrome: current status.
The Acquired Immunodeficiency Syndrome: current status.
Extended field radiotherapy is compared with both local methods of radiation and chemotherapy in the treatment of Kaposi's sarcoma. It was concluded that EFR is the treatment of choice because of its simplicity, high disease-control rate, and lack of complications in patients without systemic disease manifestations.
Kaposi's sarcoma. An update on the results of ... [Arch Dermatol. 1981] - PubMed - NCBI
Amyl nitrite may alter T lymphocytes in gays men.
Goedert JJ, Neuland CY, Wallen WC, Greene MH, Mann DL, Murray C, Strong DM, Fraumeni JF Jr, Blattner WA.
Abstract
To evaluate the recent outbreak of Kaposi's sarcoma (KS) and opportunistic infections in gays men, clinical, virological, and immunological data on two gays men with KS and on fifteen healthy gays volunteers were collected. Both KS patients had regularly used amyl or butyl nitrite (AN); they had low helper/suppressor (H/S) T-lymphocyte ratios before chemotherapy and high titres of antibody against cytomegalovirus (CMV). Eight of the fifteen volunteers were regular AN users; seven of the eight had low H/S ratios due to larger than normal numbers of OKT8-positive suppressor cells and smaller numbers of OKT4-positive helper cells. In all eight AN users the fluorescence profile obtained with monoclonal antibody 9.6 (which detects the sheep E-rosette receptor) was bimodal, indicating a subpopulation of T cells with increased receptor density. A similar pattern was observed when OKT8, the antibody which detects cytotoxic suppressor cells, was used. Two of the seven men who did not use AN had abnormal fluorescence with reagent 9.6, and one of these also had a low H/S ratio. CMV-antibody titres were persistently high in fourteen of the fifteen healthy men, but the titres were not related to AN use of T-cell abnormalities. The data suggest that nitrites may be immunosuppressive in the setting of repeated viral antigenic stimulation and may contribute to the high frequency of DS and opportunistic infections in gays men.
Amyl nitrite may alter T lymphocytes in gays men. [Lancet. 1982] - PubMed - NCBI
Chemotherapy for advanced Kaposi sarcoma. [Arch Dermatol. 1975] - PubMed - NCBI
Radiotherapy in the management of Kaposi's sarco... [Clin Radiol. 1977] - PubMed - NCBI
Radiotherapy for Kaposi's sarcoma. [Cancer. 1980] - PubMed - NCBI
Further experience with rezoxane (ICRF 159; -- NSC --129943) in treating Kaposi's sarcoma.
Olweny CL, Sikyewunda W, Otim D.
Abstract
47 patients with histologically proven Kaposi's sarcoma were treated with multiple courses of Rezoxane (each course: 1 g/m2/day for 3 days) orally. The overall response was 57% with 20% achieving complete response. The median remission duration of the complete responders is 12 months (range 2--26) with 6 still having sustained complete remissions. Most of the responders were patients with nodular mixed type of Kaposi's sarcoma. The toxicity was minimal and was mainly leukopenia, alopecia and gastrointestinal disturbance. Rezoxane is a useful safe drug and easy to administer to patients with Kaposi's sarcoma.
Further experience with rezoxane (ICRF 159; -- NSC ... [Oncology. 1980] - PubMed - NCBI
Última edición:
:. Quizás hasta sea verdad... quizás esto sea un "desliz freudiano" y este señor haya dicho esto porque barrunte que hoy en día... no mata el SIDA, matan los "fármacos anti-VIH".
